IL6 and cancer: EGFR mutations (ΔEGFR and L858R) and TGFβ can both upregulate IL-6 expression and be associated with drug resistance, which indicates that EGFR-dependent inhibition treatment maybe not sufficient for patients harboring mutant EGFR and inhibition of IL-6/gp130/JAK/STAT3 signal can further suppress growth of cancer cells and sensitize cancer cells to the antitumor drugs in NSCLC9, 25, 26, 27.